On the evening of July 29th, Shenzhen Stock Exchange announced the gem reform and pilot registration system accepted enterprises, Liaoning he's Eye Hospital Group Co., Ltd. (hereinafter referred to as "he's Ophthalmology") and other seven enterprises applied for IPO.
It is understood that he's ophthalmology is founded by he Wei, a doctor of ophthalmology studying abroad, a member of the International Council of Ophthalmology (ICO) and his team. It is a group chain medical institution that integrates medical teaching and research, adopts a three-level eye health service model, and is committed to the whole life cycle eye health management.
He Wei and his team have introduced cataract phacoemulsification technology, vitrectomy technology and fundus laser technology since 1995. Through the continuous introduction and digestion of advanced medical technology, new medical consumables and examination and treatment equipment, the level of medical technology has been continuously improved to provide patients with accurate and personalized diagnosis and treatment programs. Through more than 20 years of practice, the company has explored a sustainable and replicable three-level eye health service model.
He's ophthalmology adopts the three-level eye health service model, and it is also a group-type chain medical institution. The company provides specialized ophthalmic diagnosis and treatment services and optometry services for ophthalmopathy patients through subordinate medical institutions and optometry stores, and realizes centralized control by formulating unified procurement standards, clinical diagnosis and treatment paths, medical quality management programs, etc. share procurement channels and medical resources to ensure the quality and safety of diagnosis and treatment services, and then ensure the overall medical quality At the same time, the company through standardized hospital construction process, professional configuration, diagnosis and treatment equipment configuration and other hospital replication model to achieve rapid layout, and constantly enhance the scale effect and brand effect.
The number of he's cataract surgery in Shenyang is among the best in Northeast China for many years in a row. According to the "reputation and Comprehensive ranking of Chinese Hospitals" released by the Institute of Hospital Management of Fudan University, he in Shenyang is the only private eye hospital on the list of ophthalmology reputation in Northeast China for three consecutive years from 2016 to 2018.
He's ophthalmology plans to raise about 494 million yuan this time. It will invest in Shenyang he's Hospital expansion project, Beijing he's new ophthalmology hospital project, Chongqing he's ophthalmology new hospital project, he's ophthalmology new optometry center project, he's ophthalmology information construction project.
The shareholders of he's ophthalmology also have a good background. For example, the Advanced Manufacturing Industry Investment Fund (Limited Partnership) of the Ministry of Finance holds 9% of the shares; Beijing Xinzhong Li Meixin Equity Investment Center (Limited Partnership) holds 8.86%, and its shareholders include Beijing Yizhuang; Dalian Neusoft Holdings Co., Ltd., which is owned by PICC and Baidu, Inc., holds 6.62%; and Gongqingcheng Pengxin Investment Management Partnership (Limited Partnership) holds 3.54%. The Central Enterprise Poverty-stricken Industrial Investment Fund Co., Ltd. holds 1.16% of the shares; in addition, robots and BGI of A-share listed companies own 6.62% and 0.9% respectively.